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Abstract IGF-1 increased 2-fold protein synthesis in cardiac
myocytes. Genistein, whether added during preincubation or with
IGF-1 at the start of incubation, significantly inhibited the IGF-
1-induced stimulation of protein synthesis, autophosphorylation
of the L-subunit of IGF-1 receptor and inhibition of ERK. When
added 1 or 6 h after IGF-1, however, genistein was without effect.
IGF-1-stimulated protein synthesis was also significantly in-
hibited by PD-098059, staurosporine, and rapamycin, but not by
wortmannin, in cardiac myocytes. Some inhibitors produced a
reduction in cell size. Activation of the ERK cascade by IGF-1
may be responsible for some of the features associated with
cardiac myocyte hypertrophy.
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1. Introduction
Left ventricular hypertrophy (LVH) is associated with im-
portant adverse cardiovascular events [1,2]. Although major
advances have been made in the understanding of the general
processes of growth and di¡erentiation of myocardial cells,
the biochemical basis of pathological cardiac hypertrophy is
still poorly understood [3]. In response to hormonal and me-
chanical stimuli [4^9], the heart adapts by hypertrophy of
individual ventricular myocytes. Because these cells are termi-
nally di¡erentiated and have lost the ability to proliferate,
cardiac growth during hypertrophy results primarily from an
increase in cellular protein content, with little or no change in
the number of the cells themselves [10].
Insulin-like growth factor-1 (IGF-1) plays an essential role
in the regulation of growth and development [11]. IGF-1 and
its receptor occur in the neonatal rat myocardium, where
IGF-1 may act in an autocrine or paracrine manner [12].
There is also clinical and experimental evidence for a role of
IGF-1 in the initiation and development of LVH [13^20].
Because IGF-1 is cardioprotective [17,21^23], an understand-
ing of its action at the molecular level is of practical concern.
IGF-1 activates multiple and complex signal transduction
pathways, some of which may be relevant to the hypertrophic
response of the heart [24]. Activation of IGF-1R in these cells
is followed by autophosphorylation of its two L-subunits, by
increases in the phosphotyrosine content of ERKs, IRS-1,
phospholipase C-Q1, and PI3-K. IGF-1 also activates speci¢c
PKC isozymes, the ERK cascade and p90 RSK sequentially,
as well as stimulating protein, but not DNA, synthesis ([24],
and unpublished observations).
The aim of this work was the further elucidation of the role
of the IGF-1 receptor in the development of hypertrophy in
neonatal rat ventricular myocytes by modulation of its signal
transduction system.
2. Materials and methods
2.1. Chemical and biochemical reagents
[Q-32P]ATP and [3H]phenylalanine were from NEN-Dupont (Bos-
ton, MA, USA). 12-O-Tetradecanoylphorbol-13-acetate (TPA), Dul-
becco’s modi¢ed Eagle’s medium (DMEM), medium 199 (M199),
protease inhibitors, bovine myelin basic protein (MBP), staurospor-
ine, ATP, genistein, wortmannin, rapamycin and other biochemicals
were purchased from Sigma (St. Louis, MO, USA) unless stated oth-
erwise. Heat-inactivated fetal calf serum (FCS), horse serum and other
tissue culture products were from Life Technologies Inc. (Gaithers-
burg, MD, USA). Antibodies raised against tyrosine-phosphorylated
proteins (anti-phosphotyrosine antibody clone 4G10) and ERK were
purchased from UBI (Lake Placid, NY, USA). ECL immunoblotting
detection reagents, autoradiographic ¢lm and prestained molecular
mass standard proteins were from Amersham International. Protein
assay reagents were from Bio-Rad (Richmond, VA, USA). Human
recombinant IGF-1 was donated by Drs. P. Valenzuela and C.
George-Nascimento (Chiron Corp., CA, USA). PD-098059 (PD)
was a gift from Dr. A.M. Saltiel (Parke-Davis, MI, USA).
2.2. Culture and treatment of ventricular myocytes
Neonatal ventricular myocytes were prepared from hearts of 1^3-
day-old Sprague-Dawley rats (Animal Breeding Facility, Faculty of
Chemical and Pharmaceutical Sciences, University of Chile, Santiago,
Chile) as described previously [24]. The myocytes, plated at a ¢nal
density of 1.4U103/mm2 on gelatin-precoated 60 mm dishes, were
con£uent and spontaneously beating after 18 h. Serum was withdrawn
for 24 h before the cells were further treated with agonists (IGF-1 10
nM or TPA 1 WM) in serum-free medium (DMEM-M199) at 37‡C.
2.3. Protein synthesis
Con£uent cells were grown to quiescence in serum-free medium for
24 h. Cardiac myocytes were preincubated for 30 min in fresh serum-
free medium in the presence or absence of genistein (a protein tyrosine
kinase inhibitor, GN, 100 WM), PD-98059 (a MEK inhibitor, PD, 100
WM), wortmannin (a PI3-K inhibitor, 100 nM), staurosporine (a pro-
tein tyrosine kinase and protein kinase C inhibitor, ST, 1 WM) and
rapamycin (a p90-rsk inhibitor, RP, 20 nM). Cells were then stimu-
lated with IGF-1 (10 nM) in fresh serum-free medium for 24 h in the
presence of [3H]phenylalanine (5 WCi/well) and the inhibitor. The cells
were washed with ice-cold PBS and 10% (w/v) trichloroacetic acid was
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added at 4‡C for 60 min to precipitate the proteins. The precipitates
were washed twice with ethanol and dissolved in 1 M NaOH; the
resulting solutions were neutralized with 1 M HCl and counted in a
liquid scintillation counter.
2.4. IGF-1R tyrosine phosphorylation
Tyrosine phosphorylation of L-subunits of IGF-1R was analyzed by
immunoblotting with an anti-phosphotyrosine antibody as previously
described [24]. Brie£y, con£uent cardiac myocytes in 60 mm dishes
were exposed to IGF-1 (10 nM) for 1 min, in the presence or absence
of GN (10^100 WM) in serum-free medium at 37‡C. Medium was then
removed by aspiration and the cells were washed twice with cold
Ca2/Mg2-free Dulbecco’s phosphate-bu¡ered saline. Myocytes
were scraped into 150 Wl of cold lysis bu¡er (see [24]). The protein
content of the lysate was determined by Bradford’s method [25] and
equal amounts of protein were separated by SDS-PAGE on 9% gels,
and then transferred electrophoretically to nitrocellulose membranes
(0.45 Wm). Tyrosine-phosphorylated L-subunits of IGF-1R were
probed with a monoclonal anti-phosphotyrosine antibody and de-
tected with horseradish peroxidase-conjugated anti-mouse immuno-
globulin using an ECL system [24].
2.5. In-gel ERK assay
Activities of MBP kinases were determined with an in-gel kinase
assay [26]. Brie£y, cells were treated with agonists, lysates were pre-
pared, and proteins resolved in 10% SDS-polyacrylamide gels contain-
ing 0.5 mg/ml MBP. ERK1 and ERK2 activities were detected by
incubation of these gels with [Q-32P]ATP and autoradiography as de-
scribed earlier [26].
2.6. Expression of results and statistical methods
Results are expressed either as means þ S.E.M. for the number of
independent experiments indicated (n) or as examples of representa-
tive experiments performed on at least two separate occasions. Stat-
istical analysis was performed using ANOVA, and comparisons be-
tween groups were performed using a protected Tukey’s t-test.
3. Results
3.1. Time-course of the e¡ect of IGF-1 on protein synthesis
in rat ventricular myocytes
After 1, 6 or 24 h exposure of con£uent cardiac myocytes
to 10 nM IGF-1, protein synthesis was increased 1.9-, 1.7-,
and 2.2-fold over control levels, respectively (Fig. 1) in the
absence of any stimulation of [3H]thymidine incorporation
(evaluated at 24 h). Cell size was also increased after 24^
48 h, although to a lesser extent than observed with phenyl-
ephrine (50 WM).
3.2. Time di¡erential e¡ect of genistein on IGF-1-induced
protein synthesis in cardiac cells
Fig. 2 shows that genistein, whether added during preincu-
bation or with IGF-1 at the start of incubation, signi¢cantly
inhibited, to values lower than those of controls, the IGF-1-
induced stimulation of protein synthesis. When added 1 or 6 h
after IGF-1, however, genistein was without e¡ect.
3.3. E¡ect of genistein on IGF-1R autophosphorylation
and ERK activation in cultured ventricular myocytes
As shown in Fig. 3A, incubation of cardiac myocytes with
IGF-1 resulted in increases in the phosphotyrosine content of
two proteins with apparent molecular masses of 96 and 100
kDa, corresponding to the two L-subunits of IGF-1R. IGF-
1R autophosphorylation (particularly of the 96 kDa band)
was much lower in neonatal cardiac myocytes preincubated
with genistein (10^100 WM) added before IGF-1. Low levels of
receptor autophosphorylation were observed when genistein
was added alone. After membranes were stripped and reblot-
ted with a polyclonal antibody directed against the L-subunit
of IGF-1R, we con¢rm both the presence of two isoforms of
the L-subunit of IGF-1R and that similar amounts of IGF-1R
protein were present in all samples (data not shown). There
were signi¢cant changes in the intensity of the ERK1 band in
the in-gel ERK assay after the pre-exposure of myocytes to
genistein and subsequent addition of IGF-1 (Fig. 3B).
3.4. E¡ect of di¡erent chemical inhibitors on IGF-1R
signaling in cultured ventricular myocytes
IGF-1-stimulated phenylalanine incorporation was signi¢-
cantly inhibited by GN, PD, ST and RP, but not WM, in
cardiac myocytes (Fig. 4). GN, PD and bisindolylmaleimide
I (a speci¢c PKC inhibitor) produced an appreciable reduc-
tion in cell size (data not shown). Cell viability (approximately
85%) was una¡ected by exposure to the above inhibitors.
4. Discussion
Cardiac hypertrophy is a compensatory adaptation of car-
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Fig. 1. E¡ect of IGF-1 on the stimulation of protein synthesis in
cultured neonatal cardiac myocytes. Cells were incubated for 24 h
in serum-free medium containing L-[2,6-3H]phenylalanine with or
without IGF-1 (10 nM). Rates of protein synthesis were determined
as described in Section 2. Results are means þ S.E.M. of four inde-
pendent experiments. Control = 31 504 þ 7486 dpm; *P6 0.01 and
**P6 0.01 vs. control; P6 0.05 vs. IGF-1 (24 h).
Fig. 2. Di¡erential time e¡ect of genistein on IGF-1-induced stimu-
lation of protein synthesis in cultured cardiac myocytes. Cells were
incubated for 24 h in serum-free medium containing L-[2,6-
3H]phenylalanine and IGF-1 (10 nM) with or without genistein
(GN, 100 WM), which was added 1 h before (B), simultaneously (S),
or at 1 or 6 h (A1h, A6h, respectively) after incubation with IGF-1.
Rates of protein synthesis were determined as described in Section
2. Results are means þ S.E.M. of three independent experiments.
Control = 12 820 þ 6444 dpm, **P6 0.01 vs. control; P6 0.01 vs.
cells incubated with IGF-1 alone.
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diac myocytes to increased hemodynamic stress or to loss of
contractile myocytes. In addition to an overall increase in cell
size, protein and RNA content, there are characteristic alter-
ations at the level of gene expression [7]. One of the most
attractive hypotheses is that trophic factors (such as IGF-1,
angiotensin II, endothelin, etc.) are produced by cardiac non-
muscle cells or by the myocytes themselves in response to
mechanical stress, and that these factors, through intracellular
signaling cascades coupled to speci¢c cell surface receptors,
regulate protein synthesis and transcription of genes of the
contractile apparatus, as well as other genes involved in cell
growth. We have demonstrated that short exposure (1 h or
less) of ventricular myocytes to IGF-1 leads to the develop-
ment of hypertrophy and that this requires a fully functional
IGF-1 receptor. Our results also show that the PKC-ERK
pathway, but not PI3-K, could be involved downstream of
IGF-1R.
Some studies have involved PKC in the development of
hypertrophy (reviewed in [10]). Both direct activation of
PKC by transfection with plasmids encoding constitutively
active PKC [27,28] or exposure to TPA [28^30] leads to devel-
opment of hypertrophy in cardiac myocytes. It has also been
suggested that a consequence of the activation of PKC is the
stimulation of the ERK cascade and this e¡ect may also be
relevant to the hypertrophic response [31,32]. The ERK cas-
cade can be activated by several hypertrophic stimuli (¢bro-
blast growth factors, ET-1 and K1-adrenergic agonists, TPA)
and by stretching [31^33], and, to a lesser extent, by bradyki-
nin [34]. This has prompted the suggestion that the activation
of ERK could be a convergence point through which di¡erent
stimuli exert a common hypertrophic action. We have ob-
served that ERK activation by IGF-1 is linked to PKC in
neonatal cardiac myocytes (unpublished data). It is unresolved
whether the ERK pathway is obligatory for the growth re-
sponse of cardiac myocytes to hypertrophic agonists [31,35^
40]. Our results do, however, show that inhibition of the ERK
cascade (at the level of MEK and p90-rsk) leads to a signi¢-
cant decrease in IGF-1-stimulated protein synthesis. Activa-
tion of the ERK family may be essential for the activation of
gene expression in response to hypertrophic agonists rather
than for the changes in morphology [41]. Our data imply
that activation of the ERK cascade by IGF-1 may be respon-
sible, at least in part, for the morphological changes and in-
creased protein synthesis associated with the development of
ventricular myocyte hypertrophy.
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Fig. 4. E¡ect of di¡erent inhibitors on the stimulation of protein
synthesis in cultured cardiac myocytes. Cells were preincubated in
serum-free medium with or without GN (100 WM), PD (100 WM),
WM (100 nM), ST (1 WM) or RP (20 nM) for 30 min at 37‡C. The
medium was then replaced with medium containing L-[2,6-
3H]phenylalanine and IGF-1 (10 nM) with or without inhibitor.
After 24 h exposure, rates of protein synthesis were determined as
described in Section 2. Results are means þ S.E.M. of three inde-
pendent experiments. Control = 14 194 þ 2464; **P6 0.01, *P6 0.05
vs. IGF-1 alone; P6 0.01 vs. control.
Fig. 3. E¡ect of genistein on the IGF-1-induced stimulation of phosphorylation of the L-subunit of IGF-1R and ERK activity in cultured neo-
natal cardiac myocytes. Lysates of cells pretreated for 30 min with increasing concentrations of genistein (GN) before exposure for 1 min to
IGF-1 (10 nM) were subjected to SDS-PAGE. The L-subunits of IGF-1R containing phosphotyrosine were detected by Western immunoblot-
ting as described in Section 2 (A). Denaturated samples were also subjected to SDS-PAGE in 10% gels containing 0.2 mg/ml MBP. B: A repre-
sentative result of the phosphorylation of MBP assayed in situ as described in Section 2. The arrows to the right of this panel indicate the posi-
tion of ERK2 and ERK1. Results are representative of three independent experiments. The positions of prestained molecular weight markers
(kDa) are indicated to the left of A.
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